supp.fit

Niacin: study protocols

40 study groups say how much Niacin participants took a day. These are the doses the studies gave. They are not a recommendation.

Niacin: what the research found →

Dose per serving from products

16,769 products in our catalogue print how much Niacin a serving holds.

Most common: 10 mg to 25 mg, 42% of 16,769 products.

Dose per servingProducts
1 mg or less
614
1 mg to 2.5 mg
542
2.5 mg to 5 mg
1,439
5 mg to 10 mg
2,128
10 mg to 25 mg
7,068
25 mg to 50 mg
3,044
50 mg to 100 mg
1,132
over 100 mg
802

Dose per serving from research

40 study groups in 21 studies say how much Niacin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 48% of 40 study groups.

Daily doseStudy groups
500 mg or less
1
500 mg to 1 g
19
1 g to 2.5 g
16
2.5 g to 5 g
4

Commonly used together

2 of 40 study groups took Niacin with something else, but nothing that 3 or more different studies gave.

40 study groups

Study
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention
2015 · nicotinamide group · Adults with at least two nonmelanoma skin cancers in the previous 5 years
1 g1 year—
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
2013 · ERN/LRPT · Adults with pre-existing occlusive arterial disease at high risk of vascular events, receiving statin-based LDL-lowering therapy; mean age 64.9 years, 82.7% male
2 g1424 days12,838
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial
2019 · niacin-laropiprant · Patients at high risk of vascular disease
2 g1424 days12,838
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
2008 · ERN · Adults with dyslipidaemia (primary hypercholesterolaemia or mixed dyslipidaemia)
1 g24 weeks543
Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19
2025 · COVit-2 nicotinamide · Adults aged 18–75 with recent mild-to-moderate COVID-19 and at least one symptom; the RFITT primary-analysis population also had at least one risk factor for severe COVID-19
1 g4 weeks448
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
2008 · ERN 1 g · Dyslipidemic patients
1 g8 weeks—
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
2008 · ERN 1 g plus LRPT 18.75 mg, then doubled doses · Dyslipidemic patients
1 g8 weeks—
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
2008 · ERN 1 g plus LRPT 37.5 mg, then doubled doses · Dyslipidemic patients
1 g8 weeks—
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
2008 · ERN 1 g plus LRPT 75 mg, then doubled doses · Dyslipidemic patients
1 g8 weeks—
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
2008 · ERN 1 g plus LRPT 150 mg, then doubled doses · Dyslipidemic patients
1 g8 weeks—